Anti-SARS-CoV-2 antibodies seroprevalence among patients submitted to treatment for tuberculosis in Rio de Janeiro, Brazil: a cross-sectional study.

- Author(s): <u>Karen Machado Gomes</u><sup>a\*</sup>, Suzanne Pereira Leite<sup>a</sup>, Maria Helena Vieira
  Moutinho<sup>a</sup>, Thatiana Alfena de Souza<sup>a</sup>, Rita de Cássia Batista<sup>a</sup>, Luiz Claudio Motta de
  Oliveira<sup>a</sup>, Paulo Redner<sup>a</sup>, Jesus Pais Ramos<sup>a</sup>, Fatima Maria Gomes da Rocha<sup>b</sup>, Gisele
  Pinto de Oliveira<sup>b</sup>, Antônio Teva<sup>c</sup>, Fernando do Couto Motta<sup>d</sup>, Marilda Agudo Mendonça
  Teixeira de Siqueira<sup>d</sup>, Rafael Silva Duarte<sup>e</sup>, Francisco Inácio Pinkusfeld Monteiro
  Bastos<sup>f</sup>, <u>Paulo Victor de Sousa Viana<sup>a</sup></u>
- 10
- <sup>11</sup> <sup>a</sup> Centro de Referência Professor Helio Fraga, Escola Nacional de Saúde Pública Sergio

12 Arouca, Fundação Oswaldo Cruz – Campus Jacarepaguá, Estrada de Curicica, 2000 -

13 Curicica, Rio de Janeiro - RJ, 22780-195, Brazil.

<sup>b</sup> Vice-Diretoria de Ambulatório e Laboratório, Escola Nacional de Saúde Pública Sergio
 Arouca, Fundação Oswaldo Cruz, Av. Brasil, 4365 - Manguinhos, Rio de Janeiro - RJ,
 21040-900, Brazil.

- <sup>c</sup> Departamento de Ciências Biológicas, Escola Nacional de Saúde Pública Sergio
   Arouca, Fundação Oswaldo Cruz, Av. Brasil, 4365 Manguinhos, Rio de Janeiro RJ,
   21040-900, Brazil.
- <sup>d</sup> Laboratório de Vírus Respiratórios e Sarampo, Instituto Oswaldo Cruz, Fundação
   Oswaldo Cruz, Av. Brasil, 4365 Manguinhos, Rio de Janeiro RJ, 21040-900, Brazil.
- <sup>22</sup> <sup>e</sup> Laboratório de Micobactérias, Instituto de Microbiologia Paulo de Góes, Universidade
- Federal do Rio de Janeiro, Av. Carlos Chagas Filho, 373 bloco I Cidade Universitária,
  Rio de Janeiro RJ, 21941-970, Brazil.
- <sup>1</sup>Laboratório de Informação em Saúde, Instituto de Comunicação e Informação Científica
- 26 e Tecnológica em Saúde, Fundação Oswaldo Cruz, Av. Brasil, 4365 Manguinhos, Rio
- 27 de Janeiro RJ, 21040-900, Brazil.
- 28 \* Corresponding author: <u>karen.gomes@ensp.fiocruz.br</u>
- 29

### 30 ABSTRACT

Due to tuberculosis (TB) patients' pulmonary damages, some authors believe that a SARS-CoV-2 coinfection may result in unfavorable outcomes. A cross-sectional anti-SARS-CoV-2 antibodies seroprevalence study was conducted at a TB treatment tertiary referral unit in Rio de Janeiro, Brazil, to estimate the proportion (in %) of TB patients exposed to the new coronavirus and their main outcomes. Of 83 patients undergoing TB treatment, 26.5% have already been infected by the new coronavirus. Most patients were asymptomatic (69%) or had mild COVID-19 cases (31%). Only one patient required hospitalization. Among the symptoms and signs presented, the most frequently reported
were: fever, headache, and myalgia. People with less education and less purchasing
power seemed to had been more exposed to SARS-CoV-2.

41

42 **Keywords**: COVID-19; Tuberculosis; SARS-CoV-2; Coinfection.

43

44 **1. Introduction** 

45 COVID-19 (Coronavirus Disease 2019), caused by the new Betacoronavirus 46 SARS-CoV-2, was first described in Wuhan, China, in December 2019, as responsible 47 for severe pneumonia [1], [2], among several other systemic and organ specific 48 manifestations [3]. Despite the measures taken to curb the epidemic, SARS-CoV-2 has spread throughout the world and has caused thousands of deaths. Until July 30, 2021, 49 196.794.025 cases and 4.202.385 deaths by COVID-19 had been confirmed worldwide. 50 51 As of the same date, Brazil had 19.839.369 confirmed cases and 554.497 deaths [4]. In 52 contrast to the newest infectious disease to be defined as a pandemic, tuberculosis (TB) is an ancient disease caused by Mycobacterium tuberculosis [5]. TB mainly affects the 53 lungs and, until the COVID-19 emergence, it was the leading death caused by a single 54 infectious agent in the world, with estimates, in 2018, of approximately 10 million cases 55 and 1.5 million deaths [6]. 56

57 Due to TB patients' pulmonary functional impairment and unfavorable outcomes 58 in consequence of putative associations with fungal, viral and bacterial pulmonary 59 infections [7]–[11], it has been suggested that TB and COVID-19 coinfection could result 60 in more severe conditions and higher mortality rates [12]. Despite many published 61 studies on COVID-19 in recent months, few have analyzed how this new disease may 62 affect TB patients.

Seroprevalence studies are essential because, in addition to estimating the 63 proportion of the population previously infected, helping to assess the time required to 64 65 reach herd immunity, it may also help to better understand disease transmission patterns [13]. Therefore, to plan an adequate public health response to tuberculosis patients in 66 67 pandemic times, ideally discerning and anticipating the present and future disease dynamic, the anti-SARS-CoV-2 antibodies level may be crucial. Although some antibody 68 seroprevalence studies for SARS-CoV-2 have been published [13]-[18], none have 69 70 focused on TB patients (to the best of our knowledge). Thus, we aimed to estimate the seroprevalence of SARS-CoV-2 antibodies in patients undergoing TB treatment and 71 72 investigate the demographic and clinical characteristics of this population exposed to the 73 new coronavirus.

74

- 75 **2. Methods**
- 76

### 77 2.1 Study design

A cross-sectional anti-SARS-CoV-2 antibodies seroprevalence study was carried out among a convenience sample of TB and drug-resistant TB (DR-TB) patients assisted at a tertiary referral unit in Rio de Janeiro, Brazil. Participants were screened between September 01, 2020 up to February 28, 2021.

82

### 83 2.2 Study Subjects

The *Centro de Referência Professor Hélio Fraga* (CRPHF) is a tertiary reference health unit for TB located in Rio de Janeiro city, Rio de Janeiro, Brazil. Rio de Janeiro is the capital of the homonymous Brazilian state, which has reported the highest new case numbers of TB in 2019 (93.7 cases per 100,000 inhabitants) [6]. Rio de Janeiro was also one of the Brazilian cities with the highest COVID-19 number in 2020, couting 215,016 confirmed [19].

The CRPHF outpatient clinic treats patients with DR-TB, including multidrugresistant TB (MDR-TB), extensively drug-resistant TB (XDR-TB), and TB special cases (patients with susceptible-TB who need different treatments due to basic regimen adverse effects). The present study included patients under medical care at the CRPHF undergoing treatment for TB or TB-DR, aged 18 years old or more.

95

## 96 **2.3 Data collection**

Participants answered short standard questionnaires, including socio demographic information, symptoms related to COVID-19, and access to COVID-19
 diagnostic tests. Medical records were accessed to investigate clinical and therapeutic
 TB information.

101

#### 102 2.4 SARS-CoV-2 serological test

Antibodies prevalence was assessed by the rapid test TR DPP<sup>®</sup> COVID-19 IgM/IgG (Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil), using one drop of blood from a finger prick sample. It is an immunochromatographic test on a differentiated doublepath platform for the qualitative detection of IgM and IgG antibodies anti-SARS-CoV-2 virus. An electronic device (Micro Reader DPP®) was used to assist in the interpretation of results, reactive or non-reactive.

The TR DPP<sup>®</sup> COVID-19 IgM/IgG (Bio-Manguinhos) was licensed by the Brazilian
 Health Surveillance Agency (ANVISA) in April 2020 [20]. According to the manufacture
 specifications its sensitivity was estimated as 79% (95%CI:70.9-86.8%) for IgM and 95%

(95%Cl:88.8-97.9%) for IgG. The specificity for IgM was estimated as 98.0%
(95%Cl:95.8-99%) and 97% (95%Cl:94-98%) for IgG.

114

# 115 2.5 SARS-CoV-2 Real time RT-PCR (RT-qPCR)

The SARS-CoV-2 RT-qPCR was performed for all patients. Naso and 116 117 oropharyngeal secretions were collected and subjected to total RNA extraction using QIAmp Viral RNA Mini kit (Qiagen, Hilden, Germany). SARS-CoV-2 detection was 118 119 carried out by SARS-CoV-2 RT-gPCR using the SARS-CoV-2 Molecular E/RP kit 120 (Biomanguinhos, Rio de Janeiro, Brazil) based on the protocol previously designed by 121 Corman et al. [21]. The analyzes were performed at the Respiratory and Measles Viruses 122 Laboratory of the Oswaldo Cruz Institute (IOC/Fiocruz - SARS-CoV-2 National 123 Reference Laboratory for the Brazilian Ministry of Health).

124

# 125 2.6 Data analyses

The enrolled patients were characterized using descriptive statistics, stratified by anti-SARS-CoV-2 antibody results. Groups were compared using Fisher's exact test for categorical variables. Anti-SARS-CoV-2 antibodies prevalence and 95% CIs were calculated as the number of positive test results divided by the total number of participants.

Data were collected in electronic forms organized on *FormSus* version 3.0 (DATASUS), and all analyses were performed using R version 4.1.1 and R Studio version 1.2.1335 software (R Foundation for Statistical Computing).

134

### 135 2.7 Ethical considerations

This study was reviewed and approved by the research ethics committee of the Sergio Arouca National School of Public Health / Oswaldo Cruz Foundation (CAAE: 32219620.9.0000.5240). Written informed consent was obtained from all study participants.

140

# 141 **3. Results**

A total of 83 participants were interviewed and tested for SARS-CoV-2. Overall study participants were male (60%), 30-59 age group (65%), brown (46%) and 72% with eight or more years of schooling. 39% of participants lived in impoverished communities and 58% declared have a monthly income between one and three minimum wages (Brazilian minimum wages - R\$ 1,100, about \$219 [at the time of their assessment]). Only 14% of participants reported having been previously tested by RT-qPCR for COVID-19 diagnosis, while 25% reported having undergone rapid serological testing. Furthermore, 4.8% stated having had COVID-19 previously. About TB, most participants
had pulmonary TB (88%), 70% were new cases and 73% were DR-TB, of which 33%
were MDR-TB. The baseline population study characteristics are depicted in **Table 1**.

A total of 22 (26.5%; 95%CI:17.0-36.0%) individuals were seropositive for anti-152 153 SARS-CoV-2 antibodies. The prevalence by demographics and clinical characteristics is shown in Table 1, highlighting: 28.6% (Cl95%:4.9-52.2) for people between 19 to 29 154 155 years old, 30.4% (CI95%:13.1-53.5) for people with less than eight years of schooling, 156 25.0% (CI95%:10.0-40.0) people living in slums, and 27.1% (CI95%:14.5-39.6) patients 157 that receive monthly income between one and three salaries. SARS-CoV-2 antibodies 158 seropositive results were only observed in patients with pulmonary TB (seroprevalence 159 30.1%; CI95%:20.0-42.0). For individuals with DR-TB, the point seroprevalence was 160 29.5% (95%CI:18.0-40.9) whereas for susceptible TB was 18.2% (CI95%:2.0-34.3).

By RT-PCR, SARS-CoV-2 was detected in three patients (Table 2: patients 2, 7 161 and 18). Patients 2 and 18 non-reagents in the serological test, while patient 7 162 163 seropositive. Four patients reported having been previously COVID-19 diagnosed (Table 164 2: patients 2, 5, 22 and 23). Patients 2 and 5, the diagnostic test has been performed 165 approximately 30 days before the interview. Patient 2 presented positive RT-PCR and a 166 negative serological test. Patient 5 presented only a positive serological test. Patients 22 167 and 23, the diagnostic test has been performed nine months before the enrollment in the study and both presented negative results of either RT-PCR and serological test. 168

Adding to patients with a positive serology for SARS-CoV-2, those who detection by RT-PCR and had been previously diagnosed with COVID-19, there were 26 positive patients, 69% (18/26) of them asymptomatic. Among the 31% (8/26) who had had symptoms, 50% reported having up to 4 signs and the other half declared to have had from five to ten. The most common symptoms reported were fever, headache, and myalgias, each one with 75% of reports (multiple answers allowed) (**Table 3**).

Among all patients included, 53% (44/83) reported belonging to some priori defined risk group for COVID-19, the most frequently reported were: to be aged over 60 years old (32%) and diabetes (27%). Among patients have been infected by SARS-CoV-2, 42% (11/26) presented characteristics associated with a poor prognosis, and the most frequently reported were to be aged over 60 years (15%) and diabetes mellitus (12%) (**Table 4**).

Only one patient needed hospitalization because of COVID-19. This patient was previously COVID-19 diagnosed, and in the present study presented negative results for both RT-PCR and serology tests. This patient was diagnosed with TB after has presented COVID-19 symptoms (**Table 2**). This case was the most severe reported in the context of the present study. 186

#### 187 **4. Discussion**

188 This is the first Brazilian anti-SARS-CoV-2 antibodies seroprevalence study in TB 189 patients. The comprehensive assessment of seroprevalence is key because it provides 190 information about the extent of transmission in the past and may help to predict the future 191 course of the pandemic [13], [14]. When this kind of study targets a specific segment of 192 the population, we may infer how these people have been affected. In the present case, 193 the research focus was patients under TB and DR-TB treatment. In addition to COVID-194 19 tests, a questionnaire was also answered by the patients to assess putative 195 associations and to better understand how these patients have been affected by the 196 COVID-19 pandemic.

197 Our results showed that 26.5% of patients undergoing TB treatment had been 198 infected with the new coronavirus. However, the seroprevalence of anti-SARS-CoV-2 199 antibodies in the present study was higher than previously reported for the city of Rio de Janeiro until now, 7.5% (95%CI:4.5–11.7). This result was reported in a study carried 200 201 out between April and June 2020 and refers to the general population of Rio de Janeiro [15]. The authors also observed an increase of more than three times between surveys 202 203 performed 2 to 3 weeks apart (2.4% vs 7.5%). Between June 2020 (last month evaluated 204 by Hallal et al. [15]) and February 2021 (last month when patients were enrolled in the 205 present study), the COVID-19 confirmed cases in the city increased from 56,936 to 188,833 cases [22]. Therefore, the seroprevalence differential proportion observed when 206 207 this study is cross-compared with previous papers may be reflecting the increment in the 208 number of cases that occurred during this period. Furthermore, the fact these different 209 studies have been nested in totally different sampling strategies may help to better 210 understand such marked discrepancies [23]. Several other factors may explain the 211 observed differences, such as different timing, the different tests used in the studies, as 212 well as intrinsic differences between patients recruited in communities compared to those 213 attending health services.

214 Only one former anti-SARS-CoV-2 seroprevalence study assessed TB cases. 215 This research was carried out in Cape Town, South Africa, from August to September 216 2020. They showed that 26.7% of the subjects who reported previous TB had positive serology for SARS-CoV-2, while for the general population it was 23.7% [18]. Gao et al. 217 218 [24], in a meta-analysis of six studies conducted in China, identified a prevalence of TB 219 among patients with COVID-19 ranging from 0.47 to 4.47%. These authors found that a higher TB prevalence was identified among patients with severe COVID-19 than among 220 non-severe cases (1.47%, 10/680 vs 0.59%, 10/1703; OR: 2.1; p-value=0.24). We must 221

keep in mind that this meta-analysis refers to a set of "reverse" studies, i.e. studies
assessing TB among patients with COVID-19, instead of assessing SARS-CoV-2 among
patients under management and care for TB.

In addition to the small number of publications focused on TB and SARS-CoV-2 coinfection, published studies have presented controversial data. While some point to more severe outcomes and even a higher mortality rate among TB patients infected with the new coronavirus [24]–[26], others found a weak or no association between disease severity and/or death in TB patients diagnosed with COVID-19 [27]–[29].

230 In the present study, most patients had mild COVID-19 cases. Among patients 231 with positive serology or a COVID-19 confirmed diagnosis, 69% were asymptomatic, a 232 percentage higher than the ~30% estimated by previous studies [30]-[34]. Among 233 symptomatic patients, fever, headache and myalgia were the most frequently signs 234 reported, differing somewhat from the most common symptoms reported in other studies 235 (fever, dry cough, and dyspnea) [25], [29], [35]. This difference may be related to the fact 236 our patients presented milder COVID-19 cases vis-à-vis those from the abovementioned studies. 237

238 Although most people develop specific antibodies against SARS-CoV-2 after 239 infection, patients with milder COVID-19 symptoms seem to produce smaller amount of 240 antibodies [36]. In addition, some works have showed a decline of anti-SARS-CoV-2 antibody titers over time [36]–[38]. This information may help to explain the seronegative 241 242 results of two patients who have been COVID-19 diagnosed nine months before the 243 interview. Furthermore, the detection limit of the test and the time required to 244 seroconversion (that may varies among patients [38]), may also interfere with anti-SARS-245 CoV-2 antibodies detection. These are possible reasons for what might have happened 246 to the patient who had been COVID-19 diagnosed one month before the interview and 247 had no detected antibodies. Due to all abovementioned reasons, we cannot exclude a 248 previous infection in patients with negative serology for SARS-CoV-2.

It was impossible to infer any important correlation between the Ct value and serologic response among the patients tested, since only three subjects presented RT-PCR positive results. However, it is worthy to note that the patient which presented antibodies against the virus was the one with the highest Ct value (Ct= 34,9). Such result reinforces the well-known disconnection between virus load and humoral immune response of the patient during respiratory viral infections as observed in other diseases like influenza and syncytial respiratory virus infections.

In our study, only one patient required hospitalization, a patient diagnosed with
extrapulmonary TB 8 months after the COVID-19 symptoms. TB diagnosis after SARSCoV-2 infection has been reported by Tadolini et al. [35]. More extensive studies are

needed to understand any role of SARS-CoV-2 in the progression of TB infection todisease.

Although our small sample size did not allow us to observe significant differences among the socio-demographic categories (putative beta error), some findings should be highlighted. While 72% of respondents reported having more than 8 years of schooling, people with less education seem to be more exposed to SARS CoV-2, as well as those with less purchasing power. This data agrees with results by Horta et al. [16], who analyzed socioeconomic and ethnic status in a seroprevalence study that gathered samples from different Brazilian states.

268 The high DR-TB rate found in our study seems to be associated to the fact that 269 the approach took place in a tertiary health unit, where patients with DR-TB have been 270 mainly referred to management and care. Some authors have questioned whether DR-271 TB cases would be an additional risk factor for COVID-19 [28]. In the present study, most 272 73% (61/83) coinfected patients had TB with some resistance, and, in addition, more 273 than half of coinfected patients have undergone at least one previous TB treatment. Even 274 with these potential aggravating factors, they were asymptomatic or had mild cases of 275 COVID-19.

An important measure to curb the COVID-19 spread is mass testing. Unfortunately, this vital strategy to control the pandemic seems has not been carried out in Rio de Janeiro. In our study, 84% of respondents did not have access to RT-PCR tests and 72% to serological tests.

280 This study has some limitations. First, the possible selection bias, since the 281 sample in this study included those who naturally tend to be more mobile and less likely 282 to keep social distancing, first of all to attend their appointments at health facilities, but 283 also to address their bare necessities since most of them are poor and live in 284 impoverished and underserved communities. Second, the small sample size, notwithstanding corresponding to the caseload of a tertiary, referral, health service, are 285 likely affected by type II errors. Furthermore, questionnaires, especially when applied to 286 287 studies dealing with long-term patients, living with severe diseases, tend to be affected by both recall [39] and social desirability bias [40]. 288

289

#### 290 **5.** Conclusions

The present study sought to estimate the prevalence of COVID-19 in patients with TB treatment in Rio de Janeiro, Brazil, considering the fact that this vulnerable population is likely to be severely affected by the epidemic. The 26.5% rate of anti-SARS- 294 CoV-2 antibodies in a population with severe lung problems is of concern, although the 295 risk of serious complications and death remains controversial.

296 Knowing the anti-SARS-CoV-2 antibodies prevalence among patients is essential to better understand COVID-19 spread and help policymakers to implement 297 298 evidence-based policies to curb the epidemic and to provide coinfected patients proper 299 management and care. Our data suggest that the high seroprevalence observed among 300 TB patients may be closely associated to the low socioeconomic level of these patients, 301 besides their pressing need to attend successive appointments to manage and care their 302 underlying and putative new medical conditions. To fully adopt social distancing 303 measures in this context, despite being essential, remains a major challenge. In addition 304 to the systematic use of personal protective equipment, these patients should be 305 prioritized by vaccination efforts.

306

Acknowledgements: To all team members at the Germano Gerhardt Research
 Outpatient Clinic of the Centro de Referência Professor Hélio Fraga for their support
 during the development of this project. Bio-Manguinhos (Fiocruz) for the rapid test kits
 TR DPP® COVID-19 IgM/IgG donation. To the Respiratory Virus and Measles
 Laboratory (IOC/Fiocruz) for carrying out the SARS-CoV-2 qRT-PCR tests.

312

Funding: This research did not receive any specific grant from funding agencies in thepublic, commercial, or not-for-profit sectors.

315

### 316 **CRediT author statement**

317 Karen Machado Gomes: Conceptualization, Methodology, Investigation, Data Curation, 318 Writing - Original Draft, Review & Editing, Visualization, Supervision. Suzanne Pereira 319 Leite: Methodology, Investigation; Resources; Supervision. Maria Helena Vieira 320 Moutinho: Investigation. Thatiana Alfena de Souza: Investigation. Rita de Cássia Batista: Investigation. Luiz Claudio Motta de Oliveira: Investigation. Paulo Redner: 321 322 Investigation. Writing - Review. Jesus Pais Ramos: Writing - Review. Fatima Maria 323 Gomes da Rocha: Resources. Gisele Pinto de Oliveira: Resources. Antônio Teva: Resources, Writing - Review. Fernando do Couto Motta: Investigation. Marilda Agudo 324 Mendonça Teixeira de Siqueira: Resources. Rafael Silva Duarte: Writing - Review. 325 326 Francisco Inácio Pinkusfeld Monteiro Bastos: Writing – Review. Paulo Victor de Sousa Viana: Methodology, Formal analysis, Investigation, Resources, Data Curation, 327 328 Writing Original Draft, Review & Editing.

329

330 **Declaration of interest:** None

#### 331 References

- F. Wu *et al.*, "A new coronavirus associated with human respiratory disease in
  China," *Nature*, vol. 579, no. 7798, pp. 265–269, 2020.
- P. Zhou *et al.*, "A pneumonia outbreak associated with a new coronavirus of
  probable bat origin," *Nature*, vol. 579, no. 7798, pp. 270–273, 2020.
- M. Ramos-Casals, P. Brito-Zerón, and X. Mariette, "Systemic and organ-specific
  immune-related manifestations of COVID-19," *Nature Reviews Rheumatology*,
  vol. 17, no. 6. 2021.
- Johns Hopkins University and Medicine, "Coronavirus Resource Center," 2021.
  [Online]. Available: https://coronavirus.jhu.edu/map.html. [Accessed: 30-Jul351
  2021].
- A. G. Nerlich, C. J. Haas, A. Zink, U. Szeimies, and H. G. Hagedorn, "Molecular
  evidence for tuberculosis in an ancient Egyptian mummy," Lancet, vol. 350,
  no.9088, p. 1404, 1997
- 345 [6] Secretaria de Vigilância em Saúde; Ministério da Saúde, Boletim Epidemiológico
  346 Tuberculose 2020, 1st ed. Brasília/DF, 2020.
- W. Oei and H. Nishiura, "The relationship between tuberculosis and influenza
  death during the influenza (H1N1) pandemic from 1918-19," *Comput. Math. Methods Med.*, vol. 2012, no. i, 2012.
- 350 [8] C.-L. Small *et al.*, "Influenza Infection Leads to Increased Susceptibility to
  351 Subsequent Bacterial Superinfection by Impairing NK Cell Responses in the
  352 Lung," *J. Immunol.*, vol. 184, no. 4, pp. 2048–2056, 2010.
- S. Walaza *et al.*, "Influenza and tuberculosis co-infection: A systematic review," *Influenza Other Respi. Viruses*, vol. 14, no. 1, pp. 77–91, 2020.
- K. Zürcher, M. Zwahlen, M. Ballif, H. L. Rieder, M. Egger, and L. Fenner,
  "Influenza pandemics and tuberculosis mortality in 1889 and 1918: Analysis of
  historical data from Switzerland," *PLoS One*, vol. 11, no. 10, pp. 1–11, 2016.
- M. R. Jabbari amiri *et al.*, "Invasive forms of Candida and Aspergillus in sputum
  samples of pulmonary tuberculosis patients attending the tuberculosis reference
  laboratory in Ghaemshahr, Northern Iran: An analysis of samples collected
  during the past 10 years," in *International Journal of Mycobacteriology*, 2016,
  vol. 5.
- 363 [12] S. Yasri and V. Wiwanitkit, "Tuberculosis and novel Wuhan coronavirus
  364 infection: Pathological interrelationship," *Indian J. Tuberc.*, vol. 67, no. 2, p. 264,
  365 2020.
- 366 [13] X. Chen et al., "Serological evidence of human infection with SARS-CoV-2: a

systematic review and meta-analysis," Lancet Glob. Heal., vol. 9, no. 5, pp. 367 e598-e609, 2021. 368 369 [14] M. V. Murhekar et al., "SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020–January 2021," Int. 370 J. Infect. Dis., vol. 108, pp. 145–155, 2021. 371 P. C. Hallal et al., "SARS-CoV-2 antibody prevalence in Brazil: results from two 372 [15] 373 successive nationwide serological household surveys," Lancet Glob. Heal., vol. 374 8, no. 11, pp. e1390-e1398, 2020. 375 [16] B. L. Horta et al., "Prevalence of antibodies against SARS-CoV-2 according to 376 socioeconomic and ethnic status in a nationwide Brazilian survey," Rev. Panam. 377 Salud Publica/Pan Am. J. Public Heal., vol. 40, pp. 1–7, 2020. L. Amorim Filho et al., "Seroprevalence of anti-SARS-CoV-2 among blood 378 [17] donors in Rio de Janeiro, Brazil," Rev. Saude Publica, vol. 54, pp. 1–10, 2020. 379 380 [18] J. A. Shaw et al., "Higher SARS-CoV-2 seroprevalence in workers with lower 381 socioeconomic status in Cape Town, South Africa," PLoS One, vol. 16, no. 2 February, pp. 1–12, 2021. 382 383 [19] Prefeitura da Cidade do Rio de Janeiro, "Painel Rio COVID-19 - Perfil Epidemiológico 2020," 2020. [Online]. Available: 384 https://experience.arcgis.com/experience/38efc69787a346959c931568bd9e2cc 385 4. [Accessed: 15-May-2021]. 386 [20] A. N. de V. S. Anvisa, "Registro ANVISA no 397 80142170039 - TR DPP® 387 COVID-19 IGM/IGG - Bio-Manguinhos." [Online]. Available: 388 389 https://consultas.anvisa.gov.br/#/saude/25351218814202000/. [Accessed: 02-390 Aug-2020]. 391 [21] V. M. Corman et al., "Detection of 2019 novel coronavirus (2019-nCoV) by real-392 time RT-PCR," Euro Surveill., vol. 25, no. 3, 2020. 393 Fiocruz. Instituto de Comunicação e Informação Científica e Tecnológica em [22] Saúde (ICICT), "MonitoraCovid-19," 2020. [Online]. Available: 394 395 https://bigdatacovid19.icict.fiocruz.br/. [Accessed: 28-Jun-2021]. M. R. Elliott and R. Valliant, "Inference for nonprobability samples," Stat. Sci., 396 [23] 397 vol. 32, no. 2, 2017. [24] Y. Gao, M. Liu, Y. Chen, S. Shi, J. Geng, and J. Tian, "Association between 398 399 tuberculosis and COVID-19 severity and mortality: A rapid systematic review and 400 meta-analysis," J. Med. Virol., vol. 93, no. 1, pp. 194–196, 2021. N. Gupta et al., "A profile of a retrospective cohort of 22 patients with COVID-19 401 [25] 402 and active/treated tuberculosis," Eur. Respir. J., vol. 56, no. 5, pp. 3-7, 2020. 403 K. T. L. Sy, N. J. L. Haw, and J. Uy, "Previous and active tuberculosis increases [26]

404 risk of death and prolongs recovery in patients with COVID-19," Infect. Dis. 405 (Auckl)., vol. 52, no. 12, pp. 902–907, 2020. R. H. Du et al., "Predictors of mortality for patients with COVID-19 pneumonia 406 [27] caused by SARSCoV- 2: A prospective cohort study," Eur. Respir. J., vol. 55, no. 407 408 5, 2020. I. Motta et al., "Tuberculosis, COVID-19 and migrants: Preliminary analysis of 409 [28] 410 deaths occurring in 69 patients from two cohorts," Pulmonology, vol. 26, no. 4, pp. 233–240, 2020. 411 412 [29] C. Stochino, S. Villa, P. Zucchi, P. Parravicini, A. Gori, and M. C. Raviglione, 413 "Clinical characteristics of COVID-19 and active tuberculosis co-infection in an 414 Italian reference hospital," Eur. Respir. J., vol. 56, no. 1, 2020. 415 [30] CDC, "COVID-19 Pandemic Planning Scenarios," 2021. [Online]. Available: 416 https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html. 417 [Accessed: 15-Jun-2021]. 418 [31] M. Alene et al., "Magnitude of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and meta-analysis," PLoS ONE, vol. 16, 419 420 no. 3 March. 2021. 421 [32] M. A. Johansson et al., "SARS-CoV-2 Transmission from People without 422 COVID-19 Symptoms," JAMA Netw. Open, vol. 4, no. 1, 2021. [33] D. P. Oran and E. J. Topol, "The Proportion of SARS-CoV-2 Infections That Are 423 Asymptomatic : A Systematic Review," Ann. Intern. Med., vol. 174, no. 5, 2021. 424 425 [34] D. Buitrago-Garcia et al., "Occurrence and transmission potential of 426 asymptomatic and presymptomatic SARSCoV-2 infections: A living systematic 427 review and meta-analysis," PLoS Medicine, vol. 17, no. 9. 2020. 428 [35] M. Tadolini et al., "Active tuberculosis, sequelae and COVID-19 co-infection: 429 First cohort of 49 cases," Eur. Respir. J., vol. 56, no. 1, 2020. S. Yamayoshi et al., "Antibody titers against SARS-CoV-2 decline, but do not 430 [36] 431 disappear for several months," EClinicalMedicine, vol. 32, 2021. 432 W. H. Self et al., "Decline in SARS-CoV-2 Antibodies After Mild Infection Among [37] Frontline Health Care Personnel in a Multistate Hospital Network — 12 States, 433 April-August 2020," MMWR. Morb. Mortal. Wkly. Rep., vol. 69, no. 47, pp. 434 1762-1766, 2020. 435 Q. X. Long et al., "Antibody responses to SARS-CoV-2 in patients with COVID-436 [38] 19," Nat. Med., vol. 26, no. 6, 2020. 437 K. Spencer, EA; Brassey, J; Mahtani, "Recall bias," Catalogue of Bias 2017, 438 [39] 439 2017. [Online]. Available: https://www.catalogueofbiases.org/biases/recallbias%0A%0A. [Accessed: 30-440

441 Jul-2021].

[40] T. L. Deshields, R. C. Tait, J. D. Gfeller, and J. T. Chibnall, "Relationship
between social desirability and self-report in chronic pain patients," Clin. J. Pain
vol. 11, no. 3, 1995

Table 1. SARS-CoV-2 seroprevalence, sociodemographic indicators, previous tests and tuberculosis profile of patients under tuberculosis
 treatment assisted by a tertiary referral unit in Rio de Janeiro, Brazil.

Characteristic	Number of patients	Positive result	Prevalence <sup>1</sup>	IC95%	p-value <sup>2</sup>
Overall	83	22	26.5	17.0-36.0	
Sex					0.16
Female	33 (40%)	6	18.2	7.0-35.4	
Male	50 (60%)	16	32.0	19.5-46.7	
Age (years)					>0.99
19 to 29 years old	14 (17%)	4	28.6	4.9-52.2	
30 to 59 years old	54 (65%)	14	25.9	14.2-37.6	
≥60 years old	15 (18%)	4	26.7	9.4-57.2	
Schooling					0.59
≥ 8 years	60 (72%)	15	25.0	14.0-35.9	
< 8 years	23 (28%)	7	30.4	13.1-53.5	
Ethnicity					>0.99
Branco (White)	19 (23%)	5	26.3	6.5-46.1	
Pardo (Brown)	38 (46%)	10	26.3	12.3-40.3	
Preta (Black)	26 (31%)	7	26.9	9.9-44.0	
Slum dweller					0.81
No	51 (61%)	14	27.4	15.2-39.7	

Yes	32 (39%)	8	25.0	10.0-40.0	
Monthly income					0.26
> 1 minimum wage	19 (23%)	4	21.1	2.7-39.4	
1 to 3 minimum wages	48 (58%)	13	27.1	14.5-39.6	
3 to 5 minimum wages	2 (2.4%)	0	0	-	
Did not answer	14 (17%)	5	35.7	10.6-60.8	
Previous Covid-19					>0.99
No	77 (93%)	21	27.3	17.3-37.2	
Yes	4 (4.8%)	1	25.0	0.6-80.6	
Previous RT-PCR					0.63
No	70 (84%)	20	28.6	17.9-39.1	
Yes	12 (14%)	2	16.6	2.1-48.4	
Unable to inform	1 (1.2%)	0	0	-	
Previous rapid serological test					0.88
No	60 (72%)	17	28.3	16.9-39.7	
Yes	21 (25%)	5	23.8	5.5-42.0	
Unable to inform	2 (2.4%)	0	0	-	
TB Clinic Form					0.17
Pulmonary	73 (88%)	22	30.1	20.0-42.0	
Extrapulmonary	7 (8.4%)	0	0	-	
Both	3 (3.6%)	0	0	-	
Tuberculosis type					0.30

Susceptible TB	22 (27%)	4	18.2	2.0-34.3	
Resistant TB	61 (73%)	18	29.5	18.0-40.9	
Resistance profile					0.14
Monorresistant	8 (9.6%)	3	37.5	4.0-71.0	
RMP-Resistant	16 (19%)	4	25.0	3.7-46.2	
MDR-TB	27 (33%)	5	18.5	3.9-33.2	
Polyresistant	5 (6.0%)	3	60.0	14.6-94.7	
XDR-TB	5 (6.0%)	3	60.0	14.6-94.7	
Not applicable	22 (27%)	4	18.2	7.3-38.5	
Type of case					>0.99
New case	58 (70%)	16	27.6	16.1-39.1	
Failure	9 (11%)	2	22.2	2.8-60.0	
Change of therapeutic schema	6 (7.2%)	2	33.3	4.3-77.7	
Recurrence	4 (4.8%)	1	25.0	0.6-80.6	
Re-entry after abandonment	4 (4.8%)	1	25.0	0.6-80.6	
Others	2 (2.4%)	0	0	-	

<sup>1</sup> Frequency (%),<sup>2</sup> Pearson's Chi-squared test; Fisher's exact test. RMP, rifampicin; MDR-TB, tuberculosis multidrug-resistant; XDR-TB, tuberculosis extensively drug-resistant.

	Clinical Form	TB Resistance		COVID-19 Previous	Serological	RT-qPCR
	Clinical Form	Profile	treatment	Diagnosis	Test Result	Result (Ct)*
1	Pulmonary	Monoresistant	1	No	IgM and IgG	Non-detected
2	Pulmonary	RMP Resistant	No	1 month before the interview	Negative	Detected (20,7
3	Pulmonary	MDR-TB	1	No	IgG	Non-detected
4	Pulmonary	Polyresistant	1	No	IgM and IgG	Non-detected
5	Pulmonary	Monoresistant	No	1 month before the interview	IgM and IgG	Non-detected
6	Pulmonary	Polyresistant	2	No	IgG	Non-detected
7	Pulmonary	MDR-TB	1	No	IgM and IgG	Detected (34,9
8	Pulmonary	RMP Resistant	1	No	IgM and IgG	Non-detected
9	Pulmonary	Monoresistant	2	No	IgM	Non-detected
10	Pulmonary	MDR-TB	1	No	IgG	Non-detected
11	Pulmonary	RMP Resistant	No	No	IgG	Non-detected
12	Pulmonary	MDR-TB	1	No	IgG	Non-detected
13	Pulmonary	Susceptible	1	No	IgG	Non-detected
14	Pulmonary	Susceptible	No	No	IgG	Non-detected
15	Pulmonary	XDR-TB	No	No	IgG	Non-detected
16	Pulmonary	Polyresistant	1	No	IgM	Non-detected
17	Pulmonary	RMP Resistant	No	No	IgM	Non-detected
18	Pulmonary	Susceptible	No	No	Negative	Detected (24,0
19	Pulmonary	Susceptible	No	No	lgG	Non-detected

**Table 2.** Tuberculosis profile and COVID-19 test results of diagnosed patients and/or patients with SARS-CoV-2 positive serology.

20	Pulmonary	RMP Resistant	1	No	lgG	Non-detected
21	Pulmonary	XDR-TB	10	No	IgG	Non-detected
22**	Extrapulmonary	Susceptible	No	9 months before the interview	Negative	Non-detected
23	Pulmonary	Susceptible	1	9 months before the interview	Negative	Non-detected
24	Pulmonary	Susceptible	No	No	IgG	Non-detected
25	Pulmonary	XDR-TB	2	No	IgM and IgG	Non-detected
26	Pulmonary	MDR-TB	No	No	IgG	Non-detected

\* Ct values for SARS-CoV-2 target "E"; \*\*Patient who required hospitalization. RMP, rifampicin; MDR-TB, tuberculosis multidrug-resistant; XDR-TB,

tuberculosis extensively drug-resistant.

**Table 3.** Symptoms reported by patients coinfected with TB and SARS-CoV-2 assisted

451	by a tertiary referral unit in Rio de Janeiro, Brazil.
-----	--

Symptoms	Coinfected patients (%) <sup>1</sup>
ever	6 (75%)
Headache	6 (75%)
Myalgia	6 (75%)
Coryza	3 (38%)
Dry cough	3 (38%)
Smell Loss	3 (38%)
Diarrhea	3 (38%)
Dyspnea	2 (25%)
Abdominal pain	2 (25%)
Chest pain	2 (25%)
Productive cough	2 (25%)
Emesis	2 (25%)
Taste loss	2 (25%)
Sore throat	1 (13%)
Symptomatic patients	8 (31%)
Asymptomatic patients	18 (69%)

<sup>1</sup>COVID-19 diagnosed and/or SARS-CoV-2 antibodies positive patients.

452 **Table 4.** Risk factors for COVID-19 reported by patients under TB treatment assisted

453 by a tertiary referral unit in Rio de Janeiro, Brazil.

	Total	Coinfected patients <sup>1</sup>	
COVID-19 Risk factors	Total		
Over 60 years old	14 (32%)	4 (15%)	
Pregnant	1 (2.3%)	0 (0%)	
Heart disease	1 (2.3%)	0 (0%)	
Hypertension	3 (6.8%)	1 (4%)	
Diabetes	12 (27%)	3 (12%)	
Kidney disease	3 (6.8%)	1 (4%)	
Neurological disease	2 (4.5%)	1 (4%)	
Cancer	1 (2.3%)	0 (0%)	
Smoking	6 (14%)	1 (4%)	
HIV	6 (14%)	2 (8%)	
Total patients with risk factors	44 (53%)	11 (42%)	
Total patients without risk factors	35 (42%)	12 (46%)	
Did not know or want to inform	4 (5%)	3 (12%)	

454

<sup>1</sup>COVID-19 diagnosed and/or SARS-CoV-2 antibodies positive patients.